Member Info for Tillywhiz

Closing price showing 1135 ( however looks like mid price is Vwap )

Volume very thin - 35000

Vwap 1164

Consolidation + forming 12 ish base ready for next superb RNS news 👍

JFTH & all

Cost to borrow depends on availability of stock & fees can change daily - 1% easy to borrow stock 100% can’t borrow stock

Current 29% & rising on Hemo which is quite high

-

The cost to borrow stock is calculated by applying the daily borrow fee rate to the value of the borrowed shares (collateral), with the fee determined by the supply and demand for the specific stock. This cost is typically quoted as an annual percentage but assessed daily, meaning the total fee depends on the value of the shares and how long they are borrowed for.

Days to cover

Is based on volume , low volume & is difficult to cover high volume easier to cover , however the risk is with sudden spike in stock price like RNS & margin call will come as to risky for broker .

I believe some of Hemo shorts are hedges against larger longs & others are chancer shorting groups trying to play the RNS game .

Anyhow science will crush them all if it does what says on the tin 👍

Tick up as noted 👍

Current live

1120 - 1220

Vwap 1157 ( this currently mid orice )

Spread 8% 90 - forget it

Volume 3,000. Very thin in fact dry as an Arizona creek

Stock is limited & very low free float with huge spread , mms will have to make a market & entice some action .

I feel a tick up coming 👍

Cyrox & all

CDX / Hemo mentioned on Ortex yesterday

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

Continued consolidation & steady north trajectory/ position building will suffice until next quality RNS 👍

Morning all invested

Hemo science doing the talking on the stock for all invested

Rns are the clear & factual road map & we’ve had some quality of late

Short term good , medium term superb & long term Hemo biblical imo 👍🍷

Updated shorts

22,400 shares on loan - that’s only 0.5% of free float

That’s an increase of 3000 perhaps a hedge on a large long or some greedy muppet opened perhaps hoping for bad news in the interims -

Cost to borrow very high 28% & rising - so costs building on them shorts loaned

Days to cover 0.15

Flagged short by Hamilton Stuart capital last week is showing no flagged so closed last week

Some of these negative posters that appear on here like toxic blow up dolls in Del Boys van are perhaps associated to these desperate shorts with their sphincters nipping as the costs rack up .

Boom , & all

No one gives a crap , make yourself useful & go and put the kettle on & fetch some digestives

Closing price - 1220

Volume 54,000

Vwap 1220

Spread 8%

Good info & forward map in the interim results & a steady day of consolidation + steady north trajectory

Stock is limited with low free float ,

Hemo science achievements is the driver & gaining traction .

Short term good , medium term superb , long term Biblical 👍🍷

Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Pretax loss balloons to GBP5.0 million in the six months to June 30 from GBP2.8 million the year prior.

No revenue is reported, unchanged year-on-year, but bottom line suffers from GBP2.2 million foreign exchange loss compared to GBP118,520 gain the year before.

"The first half of 2025 has been one of steady and meaningful progress. Our principal focus remains the clinical development of HG-CT-1, our fms-like tyrosine kinase 3 targeted autologous CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukaemia," company says. "Alongside advancing this programme, we have recently strengthened our operational and manufacturing foundations while reducing our operating costs, secured grant and financing support, and positioned the company for potential early revenue generation under an innovative regulatory framework," it adds. Enters the second half of 2025 with "momentum and with confidence." 👍like this last bit .

Stock is limited with low free float ,

Hemo science achievements is the driver & gaining traction .

Short term good , medium term superb , long term Biblical 👍🍷

I see just the chuckle brothers left posting continuous negative dung , strange how that both starting posting roughly same time

Certainly plenty of forward map & science achievements gathering traction

Hemo doing superb science work & priority is patients , & stockholders will be rewarded as seen in last few weeks .imo

Plenty of news expected .

Thanks pawking 👍

Regarding - Tom W & the negative toxic posters on these boards ,

Your gaffer is A failed fund manager with teeth like balsa pegs ,

he failed on the longs in a gold fund a few yrs back & got booted out for losing a fortune & now makes a living as a toxic shorting muppet who thinks he’s some sort of toxic internet guru with his gaggle of gimp followers that patrol these boards .

They claim all sorts of toxic twaddle against Hemo & other stocks including to have opened a short , what size ? as I have all the shorting info upto date , a whiff of bull dung from the desperados

Very sceptical of these internet trading wannabe gurus full of their self importance , & wouldn’t surprise me if some monikers in these forums have TW hidden behind them .

What goes around comes around & I hope they all get their sphincter hair singed off & small testicles infested with fleas from a thousand rabid camels 👍

Current accurate shorts. - Ortex

19.3 k. - = 0.43 % of free float & made up of multiple small loans

Cost to borrow - 25%. Very high & costly for shorts

Days to cover 0.25

No flagged shorts open - all closed out last week .

Hemo science doing superb work & will prevail & the stock price will continue to track the news as it has - imo 👍

Price 1120

Volume 85000

Vwap 1128

Nice 70k delayed kipper - buy looking at the print

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

29-Sep-25 12:55:06 1,199.717 5,900 Unknown* 1,100.00 1,225.00 70.78k O

Not been on deck today been having my grease nipples Squeezed

Nice steady trajectory & consolidation today , after last weeks fully orchestrated shenanigans with large flagged short ,

As I noted at weekend with short detail , looks like institutional shorting vampires have had their feed & gone & taken majority of the toxic posters with them ,

Except a couple of Clingons on the starboard bow 👎

Anyhow science will prevail & the stock price will follow imo 👍

Will continue to be volatile as institutional involvement & very low free float of shares , imo

Hence last few weeks large % movements , institutions, financial groups are in full control of SP if required .

To note -

A flagged 28,000 in shares - approx £330,000 short closed over last 3 days ,

The stock was driven down to close out -that’s a lot of buying to close yet the stock got leathered , perhaps Fridays reversal rise was the buys of shorts closing being printed hence sudden rise after leathering .

All orchestrated in my opinion & some negative posters will likely be missing in action now .

Any positive RNS on P3 or results or paediatric or Estonia & none of the above matters the science will prevail .

Morning all invested

Nice to see some positivity & decent investors on the board ,

Strange how the negative & spurious posters have disappeared now the Hamilton capital short is closed . 🤔

RNS map show a clear vision for Hemo & now on the brink of commercialisation , that’s what Hemo investors have invested for

Recent RNS -

23rd Sep 2025 7:00 am RNS Hemogenyx Signs Letter of Intent. - superb - ‘ support the future development and commercialization of the therapy." Estonia - 👍

8th Sep 2025 7:00 am RNS Manufacturing Partnership with Made Scientific - ready to manufacture 👍

11th Sep 2025 7:00 am RNS-R Invitation to Participate at DCNY Summit - attending Friday to Monday - institutional audience👍

17th Sep 2025 7:00 am RNS Third Patient Safety - early signals of efficacy - crossed many scientific hurdles to get this far .

18th Sep 2025 1:16 pm RNS Holding(s) in company - TR1

ASH conference in December- Hemo expected to attend for the world to view its science- CAR T - CBR & CDX

Great company doing great science work & as noted in the RNS ‘ creating long-term value for our shareholders."

P3 stand out RNS statement -

‘quote RNS ‘ Preliminary assessment shows that original AML cells were not detectable in the patient using standard testing methods. ‘. 👍👍

Half yr results oct 3rd

P3 & paediatric updates expected + updates on CBR & CDX

Let’s hope the market shenanigans subside & get back on the north trajectory as news drops 👍

Morning all invested

Updated Shorts detail - Ortex

After yesterdays & the week’s shenanigans , sceptical as I am & leaves a foul taste in your mouth

Institutional + Financial shorting groups - Orchestrated & took full advantage of the recent rise , huge swings & volatility & mms making a bundle on the spread .

Shorts / Stock on loan

19,300 - increased yesterday as it has all week but a low % of free float - perhaps hedges or small shorts opened

2 days ago 18,000

3 days ago 16,800

Days to cover 0.18

Cost to borrow 22% - rising

Large flagged short of 28,000 in shares opened on 15 th sept

By Hamilton Stuart Capital Ltd -

Now showing closed - no flagged shorts outstanding

10,000 stock closed Wednesday

The remaining 18,000 closed Thursday / Friday

Sceptical gut feeling

- orchestrated drop - via someone dumping 1k lumps driving price down - short closes at a lower price via buying back in 12k chunks & price moves back up .

Needed a low price to exit as bought around the 13.00 mark & high costs to borrow .

Also coincidental- a few new negative posters appear over recent weeks about the time the short opened & now disappeared like a fart in a tornado .

These institutions always seem to know when an RNS is coming & have the ability to control a stock price , especially like HEMO with a low share availability/ free float , hence the huge % movements in recent weeks in both directions .

Many pis will have bottled it yesterday morning with trapdoor opened in light vol or had stop losses taken out , as I said whoever dumped / short closed were in full control .

Science will prevail & Hemo in a superb position , however with lots of media coverage & great science work it attracts the greedy institutions with toxic bot flies .

To note

Hemo Half year results are October 3rd according to Ortex

News rich period to continue imo